CTCFL and neoplasm: To explore the frequency of BORIS-positive cells within tumor cell lines, we first designed a BORIS mRNA targeting MB, and then we analyzed BORIS expression in human embryonic and ovarian tumor cell lines, respectively NCCIT and OVCAR3.